VTGN — Vistagen Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1411685 ·
Last close
$0.24
Market Cap
$10.82M
52W High
$0.80
52W Low
$0.20
ADV30
5,125,420
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 465,000 | — | -16,717,000 | -16,274,000 | 48,564,000 | 30,789,000 | 13,044,000 |
| Dec 2025 | 303,000 | — | -19,546,000 | -18,899,000 | 65,056,000 | 47,371,000 | 14,136,000 |
| Sep 2025 | 258,000 | — | -20,053,000 | -19,417,000 | 80,929,000 | 62,786,000 | 14,590,000 |
| Jun 2025 | 244,000 | — | -15,804,000 | -15,095,000 | 68,924,000 | 48,985,000 | 12,159,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,436,000
Investing CF
$-877,000
Financing CF
$30,971,000
CapEx
$-239,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-477,317,000
Inventory
—
Receivables
—
ST Investments
$14,614,000
EBIT TTM
$-72,120,000
Pretax Income TTM
$-69,678,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,501,000
EBITDA
$-69,459,000
Free Cash Flow
$-36,950,752
Enterprise Value
$-20,119,034
Total Cash
$31,730,000
Total Debt
$783,000
Shares Out
44,376,911
Trailing EPS
$-1.66
Book Value
$0.55
ROE
-166.5%
ROA
-83.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,269,000 | -72,126,000 | -69,685,000 | 48,564,000 | 13,044,000 | — | -66,436,000 |
| Mar 2025 | 486,000 | -55,973,000 | -51,418,000 | 84,341,000 | 13,951,000 | — | -42,097,000 |
| Mar 2024 | 1,064,000 | -33,021,000 | -29,362,000 | 123,653,000 | 9,367,000 | — | -25,813,000 |
| Mar 2023 | -227,000 | -59,268,000 | -59,248,000 | 21,089,000 | 9,009,000 | — | -49,716,000 |
TTM Snapshot
Revenues TTM
$495,000
NetIncome TTM
$-17,083,000
OpCashFlow TTM
$0
Assets (Latest)
$84,341,000
Forward EPS
$-1.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TOVX | Theriva Biologics, Inc. | $10.79M | $0.24 | — |
| QNRX | Quoin Pharmaceuticals, Ltd. | $10.89M | $5.42 | — |
| ASBP | Aspire Biopharma Holdings, Inc. | $10.95M | $7.81 | — |
| BFRG | BullFrog AI Holdings, Inc. | $10.42M | $0.56 | — |
| APRE | Aprea Therapeutics, Inc. | $10.14M | $0.81 | — |
News headlines (Yahoo Finance, 1h cache)
SRX Global Acquires Stake in Vistagen Therapeutics
2026-08-04 15:35 · Yahoo
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
2026-08-04 09:00 · Yahoo
Vistagen Appoints Douglas J. Williamson to its Board of Directors
2026-07-31 12:30 · Yahoo
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
2026-06-09 12:30 · Yahoo
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
2026-08-06 12:30 · Yahoo
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
2026-07-15 09:22 · Yahoo
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
2026-06-30 12:00 · Yahoo
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?
2026-05-19 11:08 · Yahoo
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
2026-08-14 12:32 · Yahoo
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-06-15 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.